Roche Palo Alto LLC

Littelfuse, Inc.

Syntex (u.s.a.) Inc.

Ro&cacute;he Palo Alto LLC

F. Hoffmann-la Roche Ag

Dov Nitzan

Francisco Javier Lopez-Tapia

Counde O'Yang

Joan Marie Caroon

Shu-Hai Zhao

Martin G Pineda

Jacob Berger

Anthony Vranicar

Keith Adrian Murray Walker

Kedar V Bhatawadekar

Lee Edwin Lowrie, Jr

Minh V Ngo

Mario G Sepulveda

Jim W Li

Christine E Brotherton-Pleiss

Terrence Joseph Connolly

Klaus K Weinhardt

Chris Richard Melville

Paul Francis Keitz

Eun Kyung Lee

Fernando Padilla

Patrick Finbar McGarry

Jr Lee Edwin Lowrie

A method of manufacturing a surface mount device includes providing at least one core device and at least one lead frame. The core device is attached to the lead frame. The core device and the lead frame are encapsulated within an encapsulant. The encapsulant comprises a liquid epoxy that when cured has an oxygen permeability of less than approximately 0.4 cm3&#xb7;mm/m2&#xb7;atm&#xb7;day.

Method for manufacturing a surface mount device

A method of manufacturing a surface mount device includes forming a plaque from a material, forming a plurality of conductive protrusions on a top surface and a bottom surface of the plaque, and applying a liquid encapsulant over at least a portion of the top surface and at least a portion of the bottom surface of the plaque. The liquid encapsulant is cured and when cured encapsulant has an oxygen permeability of less than about 0.4 cm3&#xb7;mm/m2&#xb7;atm&#xb7;day. The assembly is cut to provide a plurality of components. After cutting, the top surface of each component includes at least one conductive protrusion, the bottom surface of each component includes at least one conductive protrusion, the top surface and the bottom surface of each component include the cured encapsulant, and a core of each component includes the material.

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

[object Object]

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Compounds of the formula I: wherein m, n, Ar, Rand Rare as defined herein. Methods of making the compounds and using the compounds are disclosed.

Compounds of the formula I: wherein m, n, p, X, Ar, R, R, R, Rand Rare as defined herein. Methods of making the compounds and using the compounds for treatment of 5-HT6 receptor-mediated diseases are disclosed.

Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', Rand Rare as defined herein.

Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists

This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I:wherein Gis selected from the group consisting of a, band b,and A and Gare as defined in the specification; or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists

Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists

Growing community of inventors

San Jose, CA, United States of America

Dov Nitzan